Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE in CP-B: Tremelimumab and Durvalumab in Advanced HCC
NCT06526104Phase 2Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by UT Health San Antonio. Primary endpoint: Grade 3 or Higher Treatment Related Treatment Emergent-Adverse Events at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06526104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526104.